NCT02955394View on ClinicalTrials.gov

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 21, 2017

Primary Completion Date

February 17, 2023

Study Completion Date

February 28, 2027

Conditions
Breast Cancer
Interventions
DRUG

Enzalutamide

160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.

DRUG

Fulvestrant

500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

38138

West Cancer Center, Germantown

80045

University of Colorado, Aurora

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Colorado, Denver

OTHER

NCT02955394 - Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer | Biotech Hunter | Biotech Hunter